Description
Integrated drug discovery at Fidelta is driven by our determination to deliver efficacious, safe and differentiated preclinical candidates. Fidelta combines expertise in the areas of chemistry, pharmacology, ADME, pharmacokinetics and toxicology offering integrated discovery services to the biotech, pharmaceutical, agrochemical, food, cosmetic and chemical industries.
At Fidelta, integrated drug discovery is driven by our determination to deliver EFFICACIOUS, SAFE and DIFFERENTIATED PRECLINICAL CANDIDATES. Our integrated drug discovery platform is built upon:
• Our extensive experience in drug discovery, from target validation to early preclinical development
• A full range of in house drug discovery capabilities including chemistry, pharmacology, ADME, pharmacokinetics and toxicology
• Our therapeutic area expertise, targeting inflammation (and linked conditions in the fields of infection, oncology, metabolic disease) and antibacterials
• A strong emphasis on translational science, focusing on patients and disease-relevant test models/systems
• Our multidisciplinary team of high-performing bench scientists.
Of particular note are the extensive AAALAC accredited in vivo capabilities giving the possibility to take projects all the way to the clinic.
Specialties
Preclinical drug discovery services, Integrated drug discovery, Efficacy & Safety, AAALAC, Macrocyclic chemistry
Tell your friends
KONTAKT
RECENT FACEBOOK POSTS
facebook.comEFMC EFMC Prizes
Congratulations to our very own Mirjana Bukvic for being named the 2017 Young Medicinal Chemist in Industry by the European Federation for Medicinal Chemistry! http://www.efmc.info/content.php?langue=english&cle_menus=1201086324
NMR Pharma Day
Bruker, in collaboration with Fidelta - Galapagos Group, invites you to: NMR Pharma Day. Apply today and get more insights into recent advancements in NMR technology that have the potential of significantly impacting and benefiting pharmaceutical research and development. https://www.bruker.com/events/2017/mr/italiana/2017-nmr-pharma-day.html
Adrijana Vinter appointed new Managing Director of Fidelta Fidelta, a collaborative drug discovery company, has appointed Dr Adrijana Vinter, current head of business development, as new managing director of the company. Adrijana will commence her new role from January 1st 2017, succeeding Dr Phil Dudfield who is retiring. Adrijana obtained her PhD in Chemistry at the University of Zagreb in the field of new macrolide antibiotics and started her career in PLIVA 14 years ago working initially as a scientist. She obtained an MBA at Cotrugli Business School, Croatia, before moving into Business Development with the creation of Fidelta. She has successfully engineered and overseen the development of the Fidelta revenue stream resulting in significant year on year growth. Under the new leadership, Fidelta’s operations will continue seamlessly through delivering high quality services to the clients. http://www.fidelta.eu/resources/news/adrijana-vinter-appointed-new-managing-director-fidelta/
Found in Translation 2016 Patient samples in phenotypic assays, target and biomarker discovery
Studies using human tissue for identification and validation of novel targets, for setting up ex vivo testing systems and biomarker discovery are being performed more frequently in both academic and industry research. In addition, numerous random attempts have been made to use human material to improve drug discovery paradigms that are currently being incorporated into the novel strategies. The intention of the FIT 2016 meeting is to bring together various individuals who use patient samples as an integral part of their work (basic and drug discovery scientists, clinicians, as well as legal/regulatory representatives) and to exchange their experiences of best practices, success stories and disappointments. http://www.fidelta.eu/conferences/fit-2016/
2nd AngloCroatian Medicinal Symposium on Macrocycles Medicinal Chemistry and Beyond the Rule of Five
The objective of this symposium is to promote scientific interaction between scientists with a shared interest in the field of Macrocycles. This area is responsible for a growing number of therapeutic approaches and development candidates, all of which go ‘beyond the rule-of –five’. As a researcher in this field, come along to hear about the latest advances and also share in some of the secrets of discovering therapeutic agents which go beyond Lipinski’s rules. http://www.fidelta.eu/conferences/macrocycles-2016/
Fidelta's cover photo
Fidelta's cover photo
Fidelta's cover photo
Quiz
